|
Nasdaq Anthera Pharmaceuticals Inc., down $1.94 at 81 cents The company said its experimental lupus treatment blisibimod failed in a clinical trial, and that it has changed its development plans for the drug. Orexigen Therapeutics Inc., up 98 cents at $5.90 The FDA approved a competitor's anti-obesity drug, which some see as an indication that an approval for Orexigen's drug is more likely.
Copyright 2012 The Associated
Press. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
News | Sports | Business | Rural Review | Teaching & Learning | Home and Family | Tourism | Obituaries
Community |
Perspectives
|
Law & Courts |
Leisure Time
|
Spiritual Life |
Health & Fitness |
Teen Scene
Calendar
|
Letters to the Editor